Kornimate/medical-research-clean huggingface dataset:
pilates benefits in pediatric burn survivors

Conditions: Burns; Pilates Exercise; Pediatric Burn

Summary: this study investigated the effects of pilates exercises on lower limb muscle strength, functional capacity, and quality of life in children with burn injuries. in a twelve-week randomized clinical trial involving 60 children, those who received pilates exercises in addition to traditional physical therapy showed significant improvements in muscle strength, functional capacity, and overall quality of life compared to those who received traditional therapy alone. the findings suggest that incorporating pilates exercises into rehabilitation programs may enhance outcomes for children recovering from burn injuries.

this research focused on examining the impact of pilates exercises on lower limb muscle strength, functional capacity, and quality of life in children recuperating from burn injuries. the study, conducted as a twelve-week randomized clinical trial with 60 participants, found notable improvements in various aspects for the group receiving pilates exercises alongside traditional physical therapy. specifically, enhancements in muscle strength (including hip flexors, extensors, abductors, and more), functional capacity, and overall quality of life scores were statistically significant in the pilates group compared to those undergoing traditional therapy alone. this suggests a positive influence of pilates exercises on the rehabilitation of children with lower limb burns. the investigation delved into the potential benefits of pilates exercises, emphasizing their role in augmenting muscle strength, functional capacity, and overall well-being. the study participants, aged 10 to 15 years and recovering from lower limb burns, were randomly assigned to either a control group receiving only traditional physical therapy or a pilates group combining pilates exercises with traditional therapy. the outcomes demonstrated significant differences favoring the pilates group, not only in terms of lower limb muscle strength but also functional capacity, as assessed by the 6-minute walk test, and overall quality of life scores measured through the pediatric quality of life inventory. the findings suggest that incorporating pilates into rehabilitation programs for pediatric burn survivors can contribute positively to physical and functional recovery, potentially improving their overall quality of life.

Eligibility criteria:
inclusion criteria: children with lower limb (ll) healed burns. age between 10 and 15 years. six months post-injury. mixed deep 2nd \& 3rd degree burn. total body surface area (tbsa) between 35-55 percent. capability to walk securely without assistance. exclusion criteria: lower limb joint range of motion limits. mental illnesses. significant behavioral or cognitive impairments. incapacity to exercise. metabolic diseases. neuropathy. visual or vestibular abnormalities. medical instability.
safety and efficacy of voxilaprevir plus sofosbuvir/velpatasvir fixed dose combination in adults with chronic non-genotype 1 hcv infection

Conditions: Hepatitis C Virus Infection

Summary: the primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (vox) plus sofosbuvir/velpatasvir (sof/vel) fixed dose combination (fdc) in adults with chronic non genotype 1 hepatitis c virus (hcv) infection.


Eligibility criteria:
key inclusion criteria: * individuals with chronic hcv infection * hcv rna ≥10\^4 iu/ml at screening * hcv genotypes 2, 3, 4, 5, or 6 * cirrhosis determination; a liver biopsy may be required * screening laboratory values within defined thresholds * use of two contraception methods if female of childbearing potential or sexually active male key exclusion criteria: * pregnant or nursing female * current or prior history of hepatic decompensation * hepatocellular carcinoma (hcc) or other clinically significant malignancy * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) * history of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol note: other protocol defined inclusion/exclusion criteria may apply.
wearable noninvasive positive pressure ventilation device in copd

Conditions: Non-Invasive Ventilation

Summary: the objective is to assess the impact of a wearable noninvasive positive pressure ventilation, on physical activity and quality of life in patients with severe copd, complaining of dyspnea.

in order to avoid the occurrence of uncomfortable dyspnea, patients with chronic obstructive pulmonary disease (copd) are locked in a vicious circle of inactivity and social isolation which profoundly affects their quality of life and prognosis. a new wearable non invasive positive pressure ventilation device has been recently proposed; it can be used by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea- recovery time. the investigators hypothesize that this system, in reducing the inconvenience caused by dyspnea, would stimulate a more active lifestyle and improve quality of life. their objective is to assess the impact of this device on physical activity and quality of life in patients with severe copd, complaining of dyspnea. in this open study with no control group, participants will use the device at their convenience, according to their needs in daily life and for 4 weeks.

Eligibility criteria:
inclusion criteria: * patients with stable severe copd (with fev1 ≤50% predicted) * patients with mmrc score \> ou = 2. exclusion criteria: * exacerbate within a month prior. * using other non invasive ventilation device \> 15h per day. * have musculoskeletal or neuromuscular problem affecting balance and walking. * have cognitive problem affecting comprehension of the different évaluations or questionnaires. * have recently participated in physical training or rehabilitation program (≤ 3 months). * medical contra-indication to niv. * evolutionary pathologies (excluding copd) may be life-threatening in the short term (1 year) (cancer, neuromuscular disease rapidly changing). * simultaneously enrolled in an other clinical trial. * not affiliated to social security. * person deprived of liberty, major protected by law.
carb quality and chd in us adults

Conditions: Coronary Heart Disease

Summary: this is an analysis conducted in the nurses health study and the health professional follow-up study, both prospective cohort studies, where the investigators systematically investigated the association between carbohydrate quality using a variety of metrics in relation to coronary heart disease. this was a secondary data analysis of previously collected data in both cohorts.

in this study, the investigators studied the association between carbohydrate quality and coronary heart disease using prospective cohort studies among us adults. carbohydrate quality was evaluated using a variety of metrics including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intake, as well as the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber. the nurses' health study (nhs) and the health professionals follow up study (hpfs) started in 1984 and 1986, respectively, and were followed-up every 2-4 years thereafter until 2012. participants include in this study had up to 28y of follow-up. all participants were free of known diabetes mellitus, cancer or cardiovascular disease at baseline. cox proportional hazards regression models were used to assess the relationship between dietary measures of carbohydrate quality and incident chd (nonfatal myocardial infarction and fatal chd).

Eligibility criteria:
inclusion criteria: * participants of these two cohorts exclusion criteria: * participants with diabetes, coronary heart disease, or cancer at baseline * participants with missing exposure information at baseline * participants with implausible food frequency questionnaire info (females: kcal \ 3500; males: kcal \ 4200) * participants who left 10 or more items blank on the food frequency questionnaire
analysis of palbociclib treatment in patients with advanced breast cancer within a compassionate use programe

Conditions: Breast Cancer

Summary: in spain, palbociclib was launched last november 1st, 2017. however, since february 2015 the on-going compassionate use programme of palbociclib has enabled drug access to patients with rh+/her2- breast cancer previously treated with at least 4 treatment lines for advanced disease. during this period, approximately 400 patients have received treatment within this programme. since this population of patients more pre-treated was not included in the studies for regulatory submission, the collection of efficacy and toxicity data in the clinical practice setting is of clinical interest.


Eligibility criteria:
inclusion criteria: 1. patients with rh+ y her2- metastatic breast cancer having progressed to at least 4 previous standard treatment lines in the metastatic setting, and are not eligible to receive palbociclib in a clinical trial 2. absolute neutrophil count ≥1,500/mm3 (1.5 x 109/l) 3. platelet count ≥100,000/mm3 (100 x 109/l) 4. haemoglobin ≥9 g/dl 5. creatinine ≤1.5 x uln or creatinine clearance ≥ 60 ml/min 6. total bilirubin ≤1.5 x uln (≤3.0 x uln in case of gilbert's disease) 7. ast and/or alt ≤3 x uln (≤5.0 x uln in case of hepatic metastases) 8. alkaline phosphatase ≤2.5 x uln (≤5.0 x uln in case of hepatic or bone metastases) exclusion criteria: 1. major surgery, chemotherapy, radiotherapy, treatment with an investigational drug or any other active anticancer therapy within two weeks of treatment initiation 2. previous radiotherapy in ≥25% of bone marrow 3. qtc \>480 msec, personal or family past history of short or long qt syndrome, brugada's syndrome, or past history of qt interval prolongation, or tachycardia with torsade de pointes (tdp) 4. history of any of the following conditions within 6 months of treatment initiation: myocardial infarction, unstable angina, grade ≥2 arrhythmia (ctcae version 4.0), atrial fibrillation, coronary or peripheral artery by-pass, symptomatic congestive heart failure, stroke, or pulmonary thromboembolism 5. known hypersensitivity to palbociclib 6. current or recent suicidal ideation or behaviour
sglt2 inhibition for cardiovascular endpoint reduction in hypertension

Conditions: Atrial Hypertension

Summary: hypertension (htn) is a leading cause of cardiovascular disease (cvd). despite existing therapies, patients with htn still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (bp) control. sglt2 inhibitors (sglt2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. sglt2i reduce bp and might also improve outcomes for htn by reducing end-organ damage through diverse other actions. however, confirmation that sglt2i are clinically useful for the management of htn is required to change guidelines and clinical practice.


Eligibility criteria:
inclusion criteria: 1. age ≥60 years 2. systolic blood pressure \>140 mmhg or diastolic blood pressure \>90 mmhg in two measurements on different days for newly diagnosed hypertension, or through one measurement at the screening visit for patients with an existing diagnosis of hypertension. 3. a history of at least one cv event (myocardial infarction\* or stroke\*; stable angina or clinical evidence of coronary heart disease; peripheral arterial disease; transient ischemic attack) or the presence of at least one cardiovascular risk factor (current smoking of more than one cigarette per day during at least 1 year; ldl-cholesterol \> 4,0 mmol/l, age ≥ 75 years, esc heartscore \> 15%, bmi \> 32 kg/m2) \*excluding patients with myocardial infarction or stroke within preceding 3 months exclusion criteria:- known secondary cause of hypertension * myocardial infarction or stroke within the previous 3 months * symptomatic heart failure (including hfref, hfmef, hfpef) * history of diabetes mellitus * history of ketoacidosis * hepatic impairment (aspartate transaminase \[ast\] or alanine transaminase \[alt\] \>3x the upper limit of normal \[uln\]) * egfr \<25 ml/min/1.73 m2 (ckd-epicr 2021 formula) at visit 1 * receiving therapy with an sglt2i within 8 weeks prior to randomization or previous intolerance to an sglt2i * participation in another clinical study with an investigational product during the last month prior to enrolment * known allergy or hypersensitivity to sglt2i * women who are pregnant, nursing, or who plan to become pregnant while in the trial * any medical condition - outside the renal and cv disease area - with a life expectancy of less than 2 years based on investigator's clinical judgement * active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma) * inability to give informed consent
values interventions for increasing engagement with what is feared in individuals with specific phobias

Conditions: Specific Phobia

Summary: exposure is considered the therapy of choice for specific phobias (sps). nevertheless, therapy engagement is extremely limited. sps are maintained through avoidance of feared stimuli and as such willingness to approach what is feared constitutes a key factor that could explain limited treatment engagement. values interventions, a key element of acceptance and commitment therapy (act), might be one way to increase engagement, yet to this date limited research exists in this area. for the purposes of the current study, two brief values interventions were developed: (a) a personal and (b) a prosocial one. these will be compared to (c) a no-instructions control in increasing willingness to approach and approach behaviour towards phobic stimuli. ninety participants with flying phobia will be randomly allocated to one of the three groups. to measure willingness to engage with feared stimuli and approach behaviour two behavioural approach tasks using novel technologies (virtual reality), which aimed to expose participants to situations analogous to real life, were developed. willingness and behavioural approach towards airplanes at a one month follow up will also be assessed. therefore, it is hypothesised that: 1. participants in either of the two values intervention groups will have greater willingness to engage and approach behaviour towards feared stimuli compared to those in control, during the study tasks. 2. participants in either of the two values intervention groups will have greater willingness to engage and approach behaviour towards feared stimuli compared to those in control at follow up. additionally, as prosocial values provide an evolutionary advantage, the second study aim was to identify if they lead to greater engagement with phobic stimuli compared to personal ones. therefore, it was also hypothesised that: 3. participants in the prosocial values group will have greater willingness to engage and approach behaviour towards feared stimuli compared to those in personal values group, both during the study tasks and at follow up. 4. participants in the prosocial values group will have greater willingness to engage and approach behaviour towards feared stimuli compared to those in personal values group at follow up.


Eligibility criteria:
inclusion criteria: * age 18 or older * meeting the diagnostic and statistical manual for mental disorders 5 * good knowledge of the greek language (adequate comprehension level, reading level, and verbal communication) exclusion criteria: * severe heart disease * high blood pressure * photosensitive epilepsy

Keywords: specific phobia flying phobia exposure therapy values interventions
exercise following autologous peripheral blood stem cell transplantation

Conditions: Hematological Disease

Summary: the study evaluates the effects of a supervised exercise program on the physical performance, the mood and the complications of therapy in patients undergoing a high-dose chemotherapy followed by an autologous peripheral blood stem cell transplantation.


Eligibility criteria:
inclusion criteria: * age 18-70 * hematological disease * treatment with high-dose chemotherapy followed by autologous stem cell transplantation * understanding of written german exclusion criteria: * cardiorespiratory, metabolical, osteoarticular or immunological diseases which can be aggravated by exercise * pathological stress-ecg at admission

Keywords: high-dose chemotherapy hematological neoplasties fatigue cancer exercise sport hematologic neoplastic disorders
the efficacy of cranial electrostimulating therapy for depression and anxiety among homeless adults

Conditions: Depression; Anxiety

Summary: this is a trial of the use of cranial electrostimulating therapy for depression and anxiety among homeless adults.

cranial electrostimulating (ces) therapy is a food and drug administration (fda) approved treatment for depression and anxiety. however, there are no known studies on the use of this device with homeless adults. the objectives of this study are as follows: 1) to evaluate the acceptability and feasibility of ces as a treatment for homeless adults; and 2) to evaluate the efficacy of ces for the treatment of anxiety and depressive symptoms among homeless adults. participants will be randomly assigned to one of two treatments: sham (n=10) or ces (n=10). changes in anxiety and depressive symptoms will be evaluated over time.

Eligibility criteria:
inclusion criteria: * competent (no legal guardian) males and females between the ages of 18 to 64 * currently homeless or recent experience of homelessness, and symptoms of anxiety or depression exclusion criteria: * younger than 18 and older than 65 * patients who have attempted suicide with within the past twelve months or have active suicidal ideation will be excluded for possible safety concerns * self-reported illegal substance use in the past 30 days. recent use of nicotine and alcohol will be allowed. however, those with current intoxication will be excluded * history of a seizure disorder. * current history of autoimmune or endocrine disorder affecting the brain, unstable cardiac disease, history of skull fracture, or craniotomy * patients with pacemakers or internal electronic devices like deep brain stimulation and cochlear implants * women who are pregnant, nursing or planning to become pregnant * diagnosis of schizophrenia or schizoaffective disorder
personalized translational platform for biomarker discovery in brain tumors

Conditions: High Grade Glioma

Summary: the central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.


Eligibility criteria:
inclusion criteria: * newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast mri), prior to initiation of chemoxrt * anticipated survival ≥6 months * able to give informed consent * capable of undergoing mri and pet scans without the need for sedation or general anesthesia * male or female exclusion criteria: * prior radiation therapy and chemotherapy to the brain * active intracranial infection or nonglial brain mass. * recent large intracranial hemorrhage (\<1 month) * expected survival \<6 months * pregnant or nursing * renal failure * lives far from bwh and/or is unwilling/ unable to return for scheduled imaging visits.

Keywords: glioblastoma multiforme flt pet
the relationship between emotional regulation strategies and cognitive behavioral treatment effectiveness in childhood anxiety disorders: a longitudinal prospective study

Conditions: Anxiety

Summary: the current study will focus on two phases of anxiety process: generating anxiety (reported, direct and physiological) and emotional regulation strategies (reappraisal, mindfulness, expressive suppression and rumination). the claim is that better understanding of these phases in relation to cbt treatment will lead to better understanding of remission in anxiety and to better treatments in the future. objectives: to understand the relations between the four strategies of emotional regulation to anxiety disorder hence to understand the relation between these strategies to treatment effectiveness of children with anxiety disorder. methods: in phase one, clinically anxious adolescence before treatment (n=40) and healthy controls (n=40) will be compared. anxious adolescence are expected to have significantly higher levels of physical arousal and will use spontaneously more expressive suppression and rumination and less reappraisal and mindfulness then the healthy controls. in phase two, clinically anxious adolescence (n=40) before and after 8-12 weeks of cbt treatment will be compared. more specifically remitted patients will be compared with partially remitted patients. remitted patients are expected to show better improvement in the physical arousal, then partially remitted. more, decrease in levels of anxiety will be mediated by the four emotional regulation strategies, and the efficiency of using the reappraisal will be higher.


Eligibility criteria:
inclusion criteria: * anxious group: clinical diagnosis of one or more of the following diagnoses: generalized anxiety disorder, social anxiety, separation anxiety, panic disorder. * non anxious group: do not meet the criteria for anxiety disorders as well as for any other mental disorder exclusion criteria: * anxious group: not treated during the study in any other treatment for anxiety disorders.clinical diagnosis of one or more of the following diagnoses: psychosis, dyslexia, mental retardation, ptsd.

Keywords: anxiety, emotional regulation